Physician profile
Nabil Azar
NPI 1164428777
$15,683.78
in general payments reported to CMS, 2019-2025
56 companies · $4,171 in 2025
The $4,171 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $573 · 2021: $2,187 · 2022: $2,649 · 2023: $1,932 · 2024: $3,413 · 2025: $4,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,515.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,157.47 | 2019-2025 | Linzess, Vraylar, Viberzi |
| Astrazeneca Pharmaceuticals Lp | $1,799.56 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $1,326.14 | 2019-2025 | |
| Lilly USA, LLC | $1,249.30 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $813.26 | 2022-2025 | |
| Amgen INC. | $726.55 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $671.05 | 2019-2025 | |
| Novo Nordisk INC | $645.66 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $497.61 | 2019-2025 | Jardiance, Tradjenta |
| Phathom Pharmaceuticals, INC. | $488.45 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $445.59 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $396.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $364.21 | 2019-2025 | Spravato |
| Astellas Pharma US INC | $359.75 | 2023-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $351.85 | 2023-2025 | Rexulti, Abilify Maintena |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $345.25 | 2021-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $319.59 | 2022-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $290.51 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.54 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $192.46 | 2021-2025 | Trintellix |
| Exact Sciences Corporation | $191.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $138.28 | 2025 | Auvelity, Symbravo |
| Biohaven Pharmaceutical Holding Company Ltd. | $135.68 | 2022 | |
| Merck Sharp & Dohme LLC | $116.10 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Aimmune Therapeutics, INC. | $106.27 | 2024-2025 | Zenpep |
| Vivus LLC | $104.71 | 2023-2025 | Qsymia |
| Xeris Pharmaceuticals, INC. | $103.99 | 2023-2024 | Gvoke Hypopen |
| Almatica Pharma LLC | $90.86 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $85.74 | 2021-2023 | Airduo Digihaler |
| Ucb, INC. | $76.68 | 2022 | |
| Kyowa Kirin, INC. | $72.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $72.13 | 2019-2021 | |
| Neurelis, INC. | $59.89 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $58.98 | 2023-2025 | Linzess |
| Supernus Pharmaceuticals, INC. | $52.65 | 2022 | |
| Philips North America LLC | $47.06 | 2021-2023 | |
| Currax Pharmaceuticals LLC | $47.04 | 2022-2024 | Onzetra Xsail, Contrave |
| Dexcom, INC. | $42.91 | 2022-2024 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $38.25 | 2021 | |
| Avion Pharmaceuticals | $37.15 | 2022 | |
| Lundbeck LLC | $36.57 | 2023-2024 | Rexulti |
| Genzyme Corporation | $36.44 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $30.48 | 2019 | |
| Averitas Pharma INC. | $29.13 | 2024 | Qutenza |
| Allergan, INC. | $26.00 | 2019-2020 | |
| Eisai INC. | $24.59 | 2021 | |
| Horizon Therapeutics Plc | $21.76 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $21.48 | 2025 | Ultomiris |
| Sanofi Pasteur INC. | $20.25 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.06 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $19.74 | 2022 | |
| Biogen, INC. | $18.20 | 2021 | |
| Boston Scientific Corporation | $17.84 | 2025 | Wavewriter Alpha Prime 16 |
| Cranial Technologies, INC | $16.47 | 2023 | Doc Band |
| Nabriva Therapeutics, Plc | $15.70 | 2021 | |
| Nevro Corp. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Azar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.